Skip to menu
Skip to content
Skip to footer
Menu
Study
Research
Partners and community
About
Search
About
Faculties, schools, institutes and centres​
Strategic initiatives and projects
Strategic initiatives and projects
Office of 2032 Games Engagement
Office of 2032 Games Engagement
Strategy and governance
Our impact
Our experts
Our experts
Sport, health and inclusion
A better future for our environment
Economy of the future
Connecting people and places
The Queensland Commitment
University projects
University projects
Avalon Theatre restoration
UQ Experts
Academic Calendar
Study
Research
Partners and community
About
UQ home
News
Events
Give
Contact
Search term
UQ home
News
Events
Give
Contact
UQ home
About
UQ Experts
An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies (2018-2024)
Experts
Associate Professor Colm Keane
Principal Research Fellow
Frazer Institute
Faculty of Medicine
Colm Keane
